186 related articles for article (PubMed ID: 37447211)
21. Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis.
Arcidiacono D; Antonello A; Fassan M; Nucci D; Morbin T; Agostini M; Nitti D; Rugge M; Alberti A; Battaglia G; Realdon S
Dig Liver Dis; 2017 Jun; 49(6):630-638. PubMed ID: 28185837
[TBL] [Abstract][Full Text] [Related]
22. The Esophageal Microbiome in Health and Disease.
Corning B; Copland AP; Frye JW
Curr Gastroenterol Rep; 2018 Aug; 20(8):39. PubMed ID: 30069679
[TBL] [Abstract][Full Text] [Related]
23. Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.
Peter S; Pendergraft A; VanDerPol W; Wilcox CM; Kyanam Kabir Baig KR; Morrow C; Izard J; Mannon PJ
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00199. PubMed ID: 32955191
[TBL] [Abstract][Full Text] [Related]
24. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
[TBL] [Abstract][Full Text] [Related]
25. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
26. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
27. Cancer Risk in Barrett's Esophagus: A Clinical Review.
Beydoun AS; Stabenau KA; Altman KW; Johnston N
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37046992
[TBL] [Abstract][Full Text] [Related]
28. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
29. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
Runge TM; Abrams JA; Shaheen NJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):203-31. PubMed ID: 26021191
[TBL] [Abstract][Full Text] [Related]
31. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
32. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
33. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
34. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
35. Reduced Esophageal Contractility Is Associated with Dysplasia Progression in Barrett's Esophagus: A Multicenter Cohort Study.
Yadlapati R; Triggs J; Quader F; Eluri S; Bhatia S; Kaizer A; Pandolfino JE; Komanduri S; Gyawali P; Shaheen NJ; Menard-Katcher P; Wani S
Dig Dis Sci; 2020 Dec; 65(12):3631-3638. PubMed ID: 32026276
[TBL] [Abstract][Full Text] [Related]
36. Barrett's Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models.
Korbut E; Krukowska K; Magierowski M
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328735
[TBL] [Abstract][Full Text] [Related]
37. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
[TBL] [Abstract][Full Text] [Related]
38. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
39. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma.
Zhou J; Shrestha P; Qiu Z; Harman DG; Teoh WC; Al-Sohaily S; Liem H; Turner I; Ho V
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32650561
[TBL] [Abstract][Full Text] [Related]
40. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
